

HPV Vaccination crisis in Colombia




Rumors on safety generated a large number of presumptive cases in 2014
A major collective panic response in the population of Carmen de Bolivar
Limited political reaction among health leaders
Severe reduction in vaccine acceptance / promotion

COBERTURA VACUNAL EN COLOMBIA: CONSECUENCIAS



Cohorte 2003:
Cobertura 88%
4300 casos &
1900 muertes
evitadas



Cohorte 2007:
Cobertura 5%
220 casos
evitados

+300.000

+1.5 M

15.000

SOME INTERVENTIONS ADDRESSING THE PROFESSIONAL EDUCATION ASPECTS OF THE CRISIS

- Creation of a tailored *local task force* for the HPV vaccination
- Multiple visits and consultations, *meetings of experts* including one meeting of the HPV Prevention & Control Board in 2018
- Collaboration with ICO *e-learning program* on HPV vaccine safety
- Creation of two entries of the newsletter *HPV WORLD* in Spanish and English focusing on the damage to the preventive program and the examples deployed to reinitiate the activities



Instituto Nacional
de Cancerología-ESE
Colombia
Por el control del cáncer



e-oncología



HPV vaccine safety - Colombia edition -

HPV vaccine safety

PROGRAM & AUTHORS

PROGRAMA



1	Introducción	Dr. F. Xavier Bosch	Dra. Carolina Wiesner
2	Impacto del VPH en América Latina y en Colombia	Dra. Laia Bruni	Dr. Raúl Murillo
3	Eficacia y efectividad vacunal	Dra. Silvia de Sanjose	Dr. Joaquín Luna
4	Seguridad vacunal	Dr. F. Xavier Bosch	Dra. Sandra Beltrán
5	Aceptabilidad de la vacuna y episodio Carmen de Bolívar	Dra. Carolina Wiesner	Dra. Lina Trujillo
6	Conclusiones	Dra. Nubia Muñoz Dr. Antoni Trilla	

HPV vaccine safety

Course participants



Open Access from July 19, 2018
Continuous registration

Total **10,320**

5,109 Colombian; 5213 Other

participants

8,167

Currently active*

4,273

Evaluation passed**

52%

% completion***

* Alumnos activos (que hayan entrado mínimo una vez al aula)

** Aptos (superado el examen)

*** Curso abierto desde Julio 2018. Inscripción abierta continua.

HPV vaccine safety

PROFESSIONAL PROFILE OF FIRST 5000 PARTICIPANTS



1057 medical doctors	
- 286	OBGYN
- 441	GPs
- 73	PEDIATRICS
- 24	PREVENTIVE MEDICINE & PUBLIC HEALTH
- 233	OTHER

1529 nurses	
284	PREVENTIVE MEDICINE & PUBLIC HEALTH
101	ONCOLOGY
95	OBGYN
50	HEALTH ADMINISTRATOR
52	EMERGENCY & ICU
630	OTHER



Other profiles	
999	NURSE AUXILIARY
953	MEDICAL STUDENTS
599	HEALTH TECHNICIANS
391	OTHER

HPV vaccine safety

certificate





HPVWorld

The newsletter on Human Papillomavirus

January to December 2020 and

Executive report 2018-2020

HPVWorld

The newsletter on Human Papillomavirus

Executive Summary 2018-2020



148

Articles published



8.683

Subscribers



64.058

Visits



45.921

Readers



49,53% ¹

Bounce rate



14% ²

Conversion rate



167.733

Page views



806.185

Total impressions



448.000

Google impressions



2,23

³ Average duration of the session

1. Bounce rate: Readers who enter HPV but leave the site quickly. 50% is a good result.

2. Conversion rate: of 64,058 total visits, 8,683 readers subscribed, so the subscription rate is 14%.

3. Google impressions: these are the occasions when HPV appeared in Google results and users have seen our website in their search.



n° 142

Vacunación contra el VPH en Colombia. De la pesadilla a un resplandeciente y prometedor amanecer



Carlos Castro MD
*Liga Colombiana contra el Cáncer,
Bogotá, Colombia*
gjcastro@gmail.com



Marta Marin
*Ministerio de Salud de Colombia,
Bogotá, Colombia*
martaemsys@gmail.com



Miyerlandi Torres Agredo
Secretaria de Salud Pública Municipal
Miyerlandi.torres@cali.gov.co



Nubia Muñoz MD MPH
*Profesora Emérita del Instituto
Nacional del Cáncer, Bogotá,
Colombia*
nubia.munoz@free.fr

Twitter

Top 5 tweets

Tweets ordered from more people reached to less

2.610 people reached

2.542 people reached



HPVWorld @hvp_world · Oct 14, 2020

#HPV #Gynecology #HPVvaccination #SMGarland, #EAJoura. Vaccination to prevent vulvar and vaginal cancers 📝 "Approximately 40-50% and 40-60% of vulvar and vaginal squamous cell carcinomas, respectively, are attributable to HPV." ➡ bit.ly/2DcoGT4

VACCINATION TO PREVENT VULVAR AND VAGINAL CANCERS

“Approximately 40-50% and 40-60% of vulvar and vaginal squamous cell carcinomas, respectively, are attributable to HPV.”

SUZANNE M. GARLAND, AO, MBBS, MD, FRCPA, FRANZCOG AD EUNDEM, FACHSHM, FASM, FFSC (RCPA), FACOG HONORARY
Professor, Reproductive & Neonatal Infectious Diseases, Department of Obstetrics and Gynaecology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne Medical School, Director, Women's Centre for Infectious Diseases, Honorary Research Fellow, Infectious & Immunity, Murdoch Children's Research Institute, Past and Inaugural President of AOGIN (Asia Oceania research organization on Genital Infections and Neoplasia), Suzanne.Garland@unimelb.edu.au

ELMAR A. JOURA, MD
Associate Professor of Gynecology, Head of Departments of Obstetrics and Gynecology, Medical University of Vienna, General Hospital and Comprehensive Cancer Center Vienna, elmar.jaura@meduniwien.ac.at

www.hpworld.com

#HPVClinics #HPW

🗨️ 6 ❤️ 16 📤 📺

HPVWorld @hvp_world · Sep 8, 2020

#HPV #Pediatrics #HPVvaccinesafetyandhesitancy #CCastro, #MMarin, #NMuñoz. HPV Vaccination Crisis in Colombia 📝 "The response to the HPV vaccination crisis was late and inappropriate and the public confidence on the vaccine dropped dramatically. (...) ➡ bit.ly/3hHfTrn

HPV VACCINATION CRISIS IN COLOMBIA

“The response to the HPV vaccination crisis was late and inappropriate and the public confidence on the vaccine dropped dramatically. National coverage rates fell to as low as 14% for the first dose and 5% for the second dose in 2016.”

CARLOS CASTRO, MD
Colombian Leader against Cancer Bogotá, Colombia ccastro@unp.edu.co

MARTA MARIN
Colombian Ministry of Health maritamg@gmail.com

NUBIA MUÑOZ, MD, MPH
Emerita professor at the National Cancer Institute, Bogotá, Colombia nubia.muñoz@ncei.gov.co

www.hpworld.com

#HPVPediatrics #HPW

🗨️ 1 🔄 3 ❤️ 2 📤 📺

HPVWorld @hvp_world · Sep 8, 2020

(...)National coverage rates fell to as low as 14% for the first dose and 5% for the second dose in 2016" ➡ bit.ly/3hHfTrn

Geographical location of the readers

